Voss Capital LP Reduces Position in Kura Oncology, Inc. $KURA

Voss Capital LP cut its holdings in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 90.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,737 shares of the company’s stock after selling 275,922 shares during the period. Voss Capital LP’s holdings in Kura Oncology were worth $309,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of KURA. Jacobs Levy Equity Management Inc. boosted its position in shares of Kura Oncology by 101.6% during the third quarter. Jacobs Levy Equity Management Inc. now owns 2,224,590 shares of the company’s stock valued at $19,688,000 after buying an additional 1,121,228 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Kura Oncology by 111.6% during the fourth quarter. Renaissance Technologies LLC now owns 1,830,566 shares of the company’s stock valued at $19,020,000 after buying an additional 965,256 shares during the last quarter. Qube Research & Technologies Ltd boosted its position in shares of Kura Oncology by 63.0% during the second quarter. Qube Research & Technologies Ltd now owns 1,911,886 shares of the company’s stock valued at $11,032,000 after buying an additional 738,761 shares during the last quarter. Nan Fung Trinity HK Ltd. boosted its position in shares of Kura Oncology by 317.9% during the fourth quarter. Nan Fung Trinity HK Ltd. now owns 964,880 shares of the company’s stock valued at $10,025,000 after buying an additional 734,000 shares during the last quarter. Finally, UBS Group AG boosted its position in shares of Kura Oncology by 118.3% during the fourth quarter. UBS Group AG now owns 1,060,025 shares of the company’s stock valued at $11,014,000 after buying an additional 574,455 shares during the last quarter.

Kura Oncology Stock Up 2.1%

NASDAQ KURA opened at $9.05 on Friday. The stock’s 50-day moving average price is $9.31 and its 200-day moving average price is $9.33. The company has a quick ratio of 6.14, a current ratio of 6.15 and a debt-to-equity ratio of 0.09. Kura Oncology, Inc. has a 52 week low of $5.45 and a 52 week high of $12.49. The company has a market capitalization of $803.37 million, a P/E ratio of -2.70 and a beta of 0.36.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.05. Kura Oncology had a negative return on equity of 141.95% and a negative net margin of 411.19%.The firm had revenue of $18.27 million for the quarter, compared to the consensus estimate of $25.97 million. On average, equities research analysts predict that Kura Oncology, Inc. will post -3.47 earnings per share for the current year.

Analyst Upgrades and Downgrades

KURA has been the topic of a number of recent research reports. Oppenheimer set a $24.00 target price on Kura Oncology in a report on Thursday, May 28th. Citigroup reissued a “market outperform” rating on shares of Kura Oncology in a report on Thursday, May 28th. UBS Group reissued a “buy” rating and issued a $15.00 target price (down from $16.00) on shares of Kura Oncology in a report on Friday, March 13th. Wedbush lowered their target price on Kura Oncology from $38.00 to $36.00 and set an “outperform” rating on the stock in a report on Friday, March 6th. Finally, CLSA set a $24.00 target price on Kura Oncology in a report on Thursday, June 4th. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $25.58.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.